sleven, I am going to assume the company has always been for sale. It's just what management would want is more than a BP is willing to pay. Plenty of unprofitable biotech's get bought out. Ok, management may think this course will be successful. The share price does not predict that.
Sleven, I would actually disagree that the company has to be profitable to sell itself. I think the ONLY thing that matters is top line revenue and top line growth. The only costs that really matter in a sale are COGS, because that's the only thing going with the sale of the company.
Nobody is buying "Amarin". They are buying Vascepa. And that product would just get folded into an existing sales line, and the rest of the Amarin overhead goes away. I actually wouldn't mind Amarin running red - even significantly red - if it meant they were doing it to dramatically ramp up revenues.
Market Data 
Markets 
AI
